摘要
目的:探讨在各级宫颈病变中人类端粒酶hTERC基因的扩增情况,与宫颈脱落细胞学诊断及活检组织的病理诊断的关系。方法:应用双色间期荧光原位杂交技术(FISH)检测各级别宫颈病变脱落细胞标本中hTERC基因的扩增情况,其中正常对照20例,宫颈病变患者共100例;并将FISH检测结果与脱落细胞学及组织病理学诊断结果比较。结果:hTERC基因扩增的比例随宫颈细胞学诊断的分级增加,NILM、ASC-US、LSIL、HSIL、SCCA各组分别为(8.22±4.34)、(10.54±4.12)、(12.21+4.29)、(18.62±5.74)、(18.33±4.73),低级别病变与高级别病变之间比较差异有统计学意义(P<0.05)。宫颈活检组织CINⅠ组、CINⅡ组、CINⅢ组、宫颈癌组和正常对照组发生hTERC基因扩增的细胞比例分别为(8.56±3.14)、(11.61±4.10)、(14.86±3.11)、(21.44±5.55)和(4.11±1.71),hTERC基因扩增的比例随宫颈上皮内病变程度的升高而增加,差异有统计学意义(P<0.01)。结论:FISH技术可以检测宫颈脱落细胞中hTERC基因的扩增状态;hTERC基因扩增随宫颈病变的严重程度而增加。FISH检测hTERC基因的扩增可作为对宫颈细胞形态学及分子细胞遗传学检查的补充。
Objective： In this study, cervicovaginal specimens were analyzed by fluorescence in situ hybridization （FISH） for gain of chromosome 3q26.3 containing hTERC in variational cervical lesions. FISH findings were compared with the cytologic and histologic diagnoses. Methods： Slides were prepared from 100 liquid-based preparations from the cervix. One hundred cases of CIN/SCCA and 20 cases of normal cervix were analyzed for aberrations of 3q26 using a commercially available two-color FISH probe. The results of the cytologic analysis and those of concurrent or subsequent biopsies, when available, were compared with the FISH-detected 3q26 abnormalities. Results： Gain of 3q26 was significantly associated with the cytologic diagnosis （P〈0.01）. The number of cells with amplification of the hTERC gene was （8.22±4.34）, （10.54±4.12）, （12.21±4.29）, （18.62±5.74）and （18.33±4.73）, respectively. Patients with HSIL or SCCA cytology diagnoses had significantly higher percentages of cells with 3q26 gain than patients with NILM or ASC-US cytologic diagnoses. The number of cells with amplification of hTERC gene was （8.56±3.14）, （11.61 ±4.10）, （14.86±3.11）, （21.44±5.55） and （4.10±1.71）, respectively, in CIN1 group, CIN2 Group, CIN3 group and control group, with a significant difference （P〈0.01）. Conclusion： FISH can be performed on cervicovaginal liquid-based preparations to detect gain of 3q26. Gain of hTERC gene is associated with increased severity of the cytological and pathological diagnoses. This test may be a useful adjunct to cytology screening and molecular cytogenetic detection, especially in high-risk patients.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2010年第10期570-572,578,共4页
Chinese Journal of Clinical Oncology
基金
卫生部科研基金项目资助(编号:WKJ2007-3-001)~~
